3.44
0.19 (5.85%)
| Penutupan Terdahulu | 3.25 |
| Buka | 3.25 |
| Jumlah Dagangan | 792,970 |
| Purata Dagangan (3B) | 613,222 |
| Modal Pasaran | 300,782,208 |
| Harga / Jualan (P/S) | 0.730 |
| Harga / Buku (P/B) | 19.67 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 24 Mar 2026 |
| Margin Keuntungan | 46.54% |
| Margin Operasi (TTM) | -32.78% |
| EPS Cair (TTM) | 2.11 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 340.14% |
| Nisbah Semasa (MRQ) | 3.70 |
| Aliran Tunai Operasi (OCF TTM) | -109.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -78.01 M |
| Pulangan Atas Aset (ROA TTM) | -58.61% |
| Pulangan Atas Ekuiti (ROE TTM) | 121.75% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | X4 Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -3.5 |
| Osilator Teknikal | -0.5 |
| Purata | -1.13 |
|
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.43% |
| % Dimiliki oleh Institusi | 55.70% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Saturn V Capital Management Lp | 31 Dec 2025 | 5,800,530 |
| Kalehua Capital Management Llc | 31 Dec 2025 | 3,722,840 |
| Braidwell Lp | 31 Dec 2025 | 3,368,904 |
| Trails Edge Capital Partners, Lp | 31 Dec 2025 | 2,571,478 |
| Julat 52 Minggu | ||
| Median | 10.00 (190.70%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Stifel | 05 Dec 2025 | 10.00 (190.70%) | Beli | 3.98 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Feb 2026 | Pengumuman | X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026 |
| 02 Feb 2026 | Pengumuman | X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |